Evidence map›Paper›PMID 41646283›Full record

ArticleESMO gastrointestinal oncology2025

Total neoadjuvant therapy in early-onset versus average-onset locally advanced rectal cancer: patient characteristics and tolerance of therapy.

M L Conces, N Tursun, I Ozgur, S Yilmaz, D Elamin, S Patil, Y Bouferraa, E Gorgun, D Liska, E Weinstein and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Total neoadjuvant therapy in early-onset rectal cancer: A multicentre prospective cohort study.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

M L ConcesDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.
N TursunDepartment of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, USA.
I OzgurDepartment of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, USA.
S YilmazDepartment of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, USA.
D ElaminDepartment of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, USA.
S PatilDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, USA.
Y BouferraaDepartment of Internal Medicine, Cleveland Clinic, Cleveland, USA.
E GorgunDepartment of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, USA.
D LiskaDepartment of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, USA.
E WeinsteinDepartment of Palliative Medicine, Cleveland Clinic, Cleveland, USA.
S D KamathDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.
S R SteeleDepartment of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, USA.
A A KhoranaDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.
B LaderianDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.
T T JayakrishnanDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.
K G NairDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.
S R AmarnathDepartment of Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, USA.
E H BalagamwalaDepartment of Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, USA.
B N EstfanDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.
H KesslerDepartment of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, USA.
M J McNamaraDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.
M A ShapiroDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.
M A ValenteDepartment of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, USA.
S S KrishnamurthiDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with early-onset (EO, age <50 years) compared with average onset (AO, age ≥50 years) colorectal cancer have significantly higher rates of gastrointestinal toxicity with fluoropyrimidine and oxaliplatin therapy in the metastatic and adjuvant settings. Limited data exist regarding tolerance of total neoadjuvant therapy (TNT) when treating younger patients with locally advanced rectal cancer (LARC) despite the rising incidence of EO rectal cancer. Materials and methods: Data were abstracted from a retrospective database of patients with LARC treated with TNT from 1 January 2015 through 28 April 2021. Characteristics compared between EO and AO patients were demographic features, baseline characteristics of tumor, treatment delivery, antiemetic use, and toxicities. Results: Of 115 patients (39 EO, 76 AO), female patients constituted 51% of EO patients and 34% of AO patients ( Conclusions: Patients with EO, compared with AO, LARC receiving TNT appear to have higher rates of nausea and should be considered for enhanced antiemetic regimens.

Indexed as

early-onsetnausearectal cancersupportive caretotal neoadjuvant therapyyoung-onset

Identifiers

PMID41646283
PMCPMC12836723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.